Today’s Hot List: MacroGenics, Inc. (NASDAQ:MGNX), JPMorgan Chase & Co. (NYSE:JPM), Sprint Corporation (NYSE:S), Gilead Sciences Inc. (NASDAQ:GILD), OXiGENE, Inc. (NASDAQ:OXGN)

MacroGenics, Inc. (NASDAQ:MGNX) belongs to Healthcare sector. Its net profit margin is 9.50% and weekly performance is 10.15%. On last trading day company shares ended up $38.85. MacroGenics, Inc. (NASDAQ:MGNX) distance from 50-day simple moving average (SMA50) is 17.46%. On 6 July, MacroGenics, Inc. (NASDAQ:MGNX) provides an overview of the MacroGenics, Inc.’s pharmaceutical research and development focus.

JPMorgan Chase & Co. (NYSE:JPM) belongs to Financial sector. Its net profit margin is 40.20% and weekly performance is -0.70%. On last trading day company shares ended up $67.05. JPMorgan Chase & Co. (NYSE:JPM) distance from 50-day simple moving average (SMA50) is 1.15%. JPMorgan Chase & Co. (NYSE:JPM) has agreed to pay at least $125 million US to settle probes by U.S. authorities that the bank sought to improperly collect and sell consumer credit card debt.

Sprint Corporation (NYSE:S) shares moved down -3.08% in last trading session and ended the day at $3.78. S Gross Margin is 45.10% and its return on assets is -4.00%. Sprint Corporation (NYSE:S) quarterly performance is -23.94%. Sprint Corporation (NYSE:S) said that, it is teaming up with another retailer to add 20 more stores nationwide.

On 10 July, Gilead Sciences Inc. (NASDAQ:GILD) shares advanced 0.34% and was closed at $113.74. GILD EPS growth in last 5 year was 39.10%. Gilead Sciences Inc. (NASDAQ:GILD) year to date (YTD) performance is 21.10%. On 1 July, Gilead Sciences Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older.

OXiGENE, Inc. (NASDAQ:OXGN) ended the last trading day at $1.39. Company weekly volatility is calculated as 4.39% and price to cash ratio as 1.03. OXiGENE, Inc. (NASDAQ:OXGN) showed a weekly performance of -2.11%. Zacks upgraded shares of OXiGENE, Inc. (NASDAQ:OXGN) from a sell rating to a hold rating in a report released on Wednesday.

Leave a Reply

Your email address will not be published. Required fields are marked *